Manufacturers report positive data for tisagenlecleucel for follicular lymphoma trial

Manufacturers report, in the phase 2 ELARA trial, tisagenlecleucel met the primary endpoint of complete response rate in patients with relapsed or refractory follicular lymphoma. It is currently licensed for B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma.

PharmaTimes